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I
t is hard to imagine, given the wealth of new data
reported over the recent past, that adipose tissue at
one time was primarily considered as a passive res-
ervoir for energy deposition and storage. However,
research beginning in the early 1990s on the role of tumor
necrosis factor (TNF)-a ushered in a new era of inves-
tigation, and since that time, there has been an incredibly
rapid and substantive increase in our understanding of
underlying physiologic systems and molecular pathways
linking obesity, inﬂammation, and insulin action (1,2). Spe-
ciﬁcally, our understanding of the link between obesity and
carbohydrate metabolism has been signiﬁcantly enhanced
with the elucidation of key regulators of energy balance and
cellular insulin signaling that are complex and highly in-
tegrated (3–6). We now readily accept adipose tissue as
a key endocrine organ regulating processes throughout
the body with its signiﬁcant number of adipocyte secre-
tions. What now appears to be emerging is the elucidation
of cellular pathways that are operative at not only the
level of the adipocyte, but appear in common with those
reported in vascular tissue. Such a cellular mechanism
that may link pathophysiologic processes between adi-
pose and vascular tissue is the fractalkine chemokine
system as reported in this issue of Diabetes by Shah et al.
(7). Speciﬁcally, Shah et al. provide interesting data that
suggest that fractalkine (CX3CL1), a chemokine whose
source is the endothelium and is postulated to play a role
in atherogenesis, is also expressed in obese adipose tis-
sue and plays a role in monocyte adhesion processes.
These data provide an intriguing molecular link between
obesity-related metabolic dysfunction and cardiovascular
disease (CVD) in humans.
Fractalkine, a chemokine that signals through a single
known receptor (CX3CR1), has received considerable in-
terest in relation to the contribution to atheroscleroisis. It
has been described as a multidomain protein of exception-
ally large size, i.e., 95 kDa, and is expressed on numerous
cells, but more importantly, on activated endothelial, smooth
muscle cells, and macrophages (8,9). In addition to its large
size, another feature that is different from other members of
the cytokine family is the presence of a transmembrane an-
chor, and as such, fractalkine is capable of mediating adhe-
sion of cells expressing the G protein–coupled receptor
CX3CR1. The expression of fractalkine has reportedly been
enhanced by inﬂammatory stimuli, i.e., TNF-a,i n t e r f e r o n
(IFN)-g and lipopolysaccharide (9). It is also reported
that a soluble form can be released from its membrane
form by extracellular cleavage and then act as a classical
chemoattractant for leukocytes and also smooth muscle
cells expressing the receptor, i.e., CX3CR1 (8,9). Recently,
elegant studies in primary smooth muscle cell lines dem-
onstrated that CX3CL1 may have novel functions in regard
to antiapotosis and proliferation, and as such, have impor-
tant implications for vascular pathologies where the bal-
ance of smooth muscle cell proliferation and apotosis plays
ac r i t i c a lr o l ei nd e t e r m i n i n gp l a q u es t a b i l i t ya n dv e s s e l
stenosis (9).
The chemokine family in general and fractalkine in
particular are postulated to contribute signiﬁcantly to the
pathogenesis of CVD as leukocyte recruitment plays a role
at all stages of CVD progression from early plaque for-
mation to plaque rupture (10). The pathways by which
fractalkine may participate in the modulation of adhesion
processes at the cellular level are outlined schematically
in Fig. 1 (11). As demonstrated in the ﬁgure, fractalkine
may enhance leukocyte migration from the circulation into
the tissue by enhancing the tethering (transient, selectin-
mediated binding), triggering (activation of integrins by
chemokines), adhesion, and ﬁnally migration through the
endothelial layer. As such, enhancing or inhibiting any of
these steps can either promote or attenuate atherogenic
processes, respectively. In this regard, a preclinical study in
mice evaluated anti-inﬂammatory therapy in the form of
aspirin and plaque severity. Interestingly, anti-inﬂammatory
treatment improved the atherosclerotic lesion as assessed
by pathology image analysis. Such therapy also reportedly
suppressed the fractalkine expression as assessed by both
RT-PCR and immunohistochemical analysis, suggesting
a cause and effect (12).
However, the clinical relevance in humans has been
suggested by recent studies evaluating lesion extent and
characteristics and the association to speciﬁc markers of the
fractalkine-CX3CR1 chemokine system. Speciﬁcally, Ikejima
et al. (10) demonstrated that plasma levels of fractalkine
were signiﬁcantly increased in patients with unstable angina
pectoris with plaque rupture compared with patients with
unstable angina pectoris without plaque rupture and patients
with stable angina pectoris. In addition, they demonstrated
that CX3CR1-expressing mononuclear cells were indepen-
dent predictors of the presence of the plaque rupture (10).
Other studies have suggested that fractalkine is increased
in patients with coronary heart disease, but the beneﬁcial
effect of optimized anti-inﬂammatory therapy, i.e., statins,
ACE inhibitors and ARBs, as part of coronary artery reha-
bilitation, may reduce the levels to those of control subjects
(8). Additional studies in humans have evaluated polymor-
phisms of fractalkine that are postulated to alter ligand re-
ceptor afﬁnity, and as such, potentially inﬂuence a patient’s
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COMMENTARYsusceptibility to CVD. One such study (13) demonstrated that
a single nucleotide polymorphism (SNP) of the CX3CR1
gene (T280M) was associated with a lower risk of carotid
atheromatous disease, independent from modiﬁable ce-
rebrovascular risk factors. Interestingly, through a meta-
analysis involving over 2,000 patients with coronary artery
disease and 2,800 control subjects, the 280M allele was
associated with a reduced risk of coronary artery disease
in the heterozygous state (14). However, Debette et al.
(15) evaluated 18 polymorphisms in CX3CL1 and CX3CR1
in over 2,700 German community individuals and over 6,000
French community individuals. They reported associa-
tions of common carotid artery intima-media thickness
with three genetic variants of fractalkine and its receptor
in the German cohort, but these were not replicated in the
French cohort (15).
Based on the above, it is apparent that fractalkine, given
its function and source of expression, has an important
role in CVD. However, the importance of the current study
in this issue of Diabetes as reported by Shah et al. (7) is the
fact that this chemokine appears to also be a novel che-
mokine induced in human adipose tissue. The studies of
Shah et al. (7) were well conceived, well conducted, and
represented a comprehensive evaluation of the novel adio-
pochemokine system from basic to translational studies.
This was achieved using a variety of approaches that in-
cluded in vitro studies on primary human adipocytes, in vivo
endotoxemia studies in humans, subcutaneous adipose tis-
sue biopsies in both lean and obese subjects, and visceral
adipose tissue studies in obese subjects. To support the data
obtained in the laboratory and from the human metabolic
studies, a well designed case-control study was performed in
individuals with and without type 2 diabetes in addition to
association studies of the CX3CR1 gene variants in over
2,000 well characterized subjects. Thus, support for the
hypothesis was conﬁrmed at many different levels of
basic and clinical research.
The results deﬁnitively demonstrated that CX3CL1 is
signiﬁcantly increased in obesity and can be evoked by
induction of inﬂammation in vivo. They demonstrated that
not only is the chemokine secreted by stromal vascular
fraction of the adipose tissue, but it is also secreted by the
speciﬁc adipocytes. In addition, they demonstrated that
the fractalkine chemokine system mediates monocyte ad-
hesion to human adipocytes. The secretion of fractalkine
by the adipocyte and the observation that the system
modulates adhesion processes are important observations
of the study and clearly represent the novelty of the re-
search. In the case-control study, patients with type 2 di-
abetes were observed to have higher levels of plasma
fractalkine than nondiabetic subjects. Finally, it was also
shown that individuals that had two common nonsynon-
ymous coding SNPs in CX3CR1 (i.e., T280M and V249I)
tended to have greater waist circumference, were more
insulin resistant, and had higher leptin, but lower adipo-
nectin levels. Further, these alleles tended to be associ-
ated with the presence of metabolic syndrome and type 2
diabetes.
The data clearly suggest that the fractalkine system
represents a novel potential target for therapeutic in-
tervention for obesity and type 2 diabetes. Future studies
evaluating this system with genetic models in preclinical
FIG. 1. Schematic model of classical and fractalkine-mediated pathways in the adhesion cascade. Adapted from Umehara et al. (11). CCLs, CXCLs,
chemokines; CCRs, CXCRs, chemokine receptors.
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be important in order to further deﬁne the clinical rele-
vance of the system. But, to date, the data presented do
provide for an intriguing unifying cellular mechanism
contributing to the understanding of obesity-related dys-
function and vascular pathologies.
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